Hyaluronic acid-based gels including lidocaine
Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
1. A dermal filler comprising a sterile, stable injectable gel having a mixture of soluble form hyaluronic acid (HA), particles of HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE), and lidocaine that is freely released in vivo.
2. The dermal filler of claim 1 , wherein the lidocaine is present in an amount effective to mitigate pain upon injection of the gel.
3. The dermal filler of claim 1 , wherein the gel further comprises free HA.
4. The dermal filler of claim 1 , wherein lidocaine is at a concentration of between about 0.1% and about 5% by weight.
5. The dermal filler of claim 1 , wherein the particles of HA crosslinked with BDDE have a degree of crosslinking between about 2% and about 20%.
6. The dermal filler of claim 4 , wherein the particles of HA crosslinked with BDDE have a degree of crosslinking of less than about 6%.
7. The dermal filler of claim 1 , wherein the soluble form HA is present in an amount of about 10% to about 20% by volume.
8. The dermal filler of claim 1 , wherein the gel comprises HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE) having an average particle size of at least about 200 μm.
9. The dermal filler of claim 1 , wherein the gel comprises HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE) having an average particle size of at least about 250 μm.
10. The dermal filler of claim 1 , wherein the gel comprises HA crosslinked with 1,4-butanediol diglycidyl ether (BDDE) having an average particle size of less than about 200 μm.
11. The dermal filler of claim 1 , wherein the crosslinked HA is homogenized.
12. The dermal filler of claim 1 , wherein the dermal filler has a HA concentration between about 20 mg/mL and about 30 mg/mL.
13. The dermal filler of claim 1 , wherein the lidocaine is at a concentration of 0.3% w/w and the HA is at a concentration of between about 20 mg/mL and about 30 mg/mL.
14. The dermal filler of claim 1 , wherein the gel has a pH is from about 7 to about 7.5.
15. The dermal filler of claim 1 , wherein the gel has a pH is about 7.
16. The dermal filler of claim 1 , wherein the gel is sterilized by autoclave.
17. The dermal filler of claim 1 , wherein the gel is sterilized by heat sterilization between about 120° C. and about 130° C.
18. The dermal filler of claim 1 , wherein the lidocaine does not substantially degrade the HA during storage under ambient conditions for at least 3 months.
19. The dermal filler of claim 1 , wherein the lidocaine does not substantially degrade the HA during storage under ambient conditions for at least 6 months.
20. The dermal filler of claim 1 , wherein the lidocaine does not substantially degrade the HA during storage under ambient conditions for at least 9 months.